<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput xmlns:ns2="local" id="98593"><DrugName>two particle nicotine vaccine (smoking cessation), Selecta biosciences</DrugName><DrugSynonyms><Name><Value>two particle nicotine vaccine (smoking cessation), Selecta biosciences</Value></Name><Name><Value>SEL-070</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>SELA-070</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>nicotine (nanoparticle/subcutaneous, smoking cessation), Selecta Biosciences</Value></Name><Name><Value>54-11-5</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1045799">Selecta Biosciences Inc</CompanyOriginator><CompaniesPrimary><Company id="1045799">Selecta Biosciences Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1045799" type="Company"><TargetEntity id="4298128957" type="organizationId">Selecta Biosciences Inc</TargetEntity></SourceEntity><SourceEntity id="235" type="ciIndication"><TargetEntity id="F17.2" type="ICD10"></TargetEntity><TargetEntity id="F17" type="ICD10"></TargetEntity><TargetEntity id="10057852" type="MEDDRA"></TargetEntity><TargetEntity id="D012907" type="MeSH"></TargetEntity><TargetEntity id="-1170201411" type="omicsDisease"></TargetEntity><TargetEntity id="2624" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C1">Phase 1 Clinical</PhaseHighest><IndicationsPrimary><Indication id="235">Nicotine dependence</Indication></IndicationsPrimary><ActionsPrimary><Action id="74843">T cell receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="12379">Therapeutic vaccine</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="599">Nanoparticle formulation injectable</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><LastModificationDate>2019-06-28T04:41:51.000Z</LastModificationDate><ChangeDateLast>2019-06-24T00:00:00.000Z</ChangeDateLast><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1045799" linkType="Company"&gt;Selecta Biosciences&lt;/ulink&gt; is developing SELA-070 (SEL-070), a  nanoparticle nicotine vaccine, containing two active components (TLR agonist and  TCHP) which act as adjuvant 	formulated in separate nicotine-containing nanoparticles, using its Synthetic Vaccine Particle (SVP) platform, for the potential sc treatment of smoking cessation and prevention of relapse  [&lt;ulink linkID="1627754" linkType="Reference"&gt;1627754&lt;/ulink&gt;], [&lt;ulink linkID="1683562" linkType="Reference"&gt;1683562&lt;/ulink&gt;], [&lt;ulink linkID="1761752" linkType="Reference"&gt;1761752&lt;/ulink&gt;], [&lt;ulink linkID="1927145" linkType="Reference"&gt;1927145&lt;/ulink&gt;].   In May 2017, a  phase I study was initiated  [&lt;ulink linkID="1926986" linkType="Reference"&gt;1926986&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In May 2017,  dosing was initiated in a  double-blind, placebo-controlled, dose escalation, phase I study (NCT03148925; SELA-070/101; 2017-000534-65) to assess the safety, tolerability and pharmacodynamic profile of the vaccine, being conducted in Belgium in 48 smokers. The study was to complete in September 2018  [&lt;ulink linkID="1926986" linkType="Reference"&gt;1926986&lt;/ulink&gt;], [&lt;ulink linkID="1927145" linkType="Reference"&gt;1927145&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In May 2016, the vaccine was listed as being in preclinical development [&lt;ulink linkID="1761752" linkType="Reference"&gt;1761752&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015,   the company planned for testing the vaccine  to optimize the human anti-nicotine antibody response  [&lt;ulink linkID="1627754" linkType="Reference"&gt;1627754&lt;/ulink&gt;], [&lt;ulink linkID="1683562" linkType="Reference"&gt;1683562&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1045799">Selecta Biosciences Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="235">Nicotine dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2017-05-10T00:00:00.000Z</StatusDate><Source id="1927145" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045799">Selecta Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="235">Nicotine dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2014-05-06T00:00:00.000Z</StatusDate><Source id="1683562" type="OTHER"></Source></DevelopmentStatusCurrent></IDdbDevelopmentStatus><Targets><Target id="PTGT-12987"><Name>T cell receptor</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1045799">Selecta Biosciences Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CN1CCC[C@H]1c2cccnc2</Smiles></StructureSmiles><Deals><Deal id="155805" title="NIDA to award Selecta Bioscience funding for the development of two particle nicotine vaccine against smoking cessation  "></Deal></Deals><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput>